Enlitic builds deep-learning AI for medical imaging workflows. Its CXR-AI product analyzes chest X-rays to better detect major abnormal findings like lung nodules and consolidation, and Enlitic became the first U.S. imaging AI company to receive regulatory approval to commercialize in Japan with that product. Its ENDEX platform uses AI to standardize medical image data descriptions so studies are accurately labeled and easily findable across large archives.
Standardizing historical and new image data labeling (ENDEX) solves a less visible but genuinely important problem – hospital imaging archives accumulate over decades under inconsistent labeling conventions, and unstandardized data is effectively unusable for both clinical retrieval and building the real-world evidence datasets Enlitic’s broader Curie platform is meant to support. Early applications of the underlying technology were measured to speed up radiologist interpretation by over 20% while improving true-positive rates and cutting false positives by more than 10%.
This is enterprise healthcare-imaging infrastructure sold to hospitals and health systems, not a consumer or individual-practitioner tool. Regulatory approval status matters more here than for most software categories – Japan approval for CXR-AI is a concrete, verifiable claim rather than marketing language.
